港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

杭州先为达生物科技股份有限公司（临时代码）

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

香港流通股本：- -

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

市销率: - -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

全球首个cAMP偏向型GLP-1上市！先为达生物改写赛道格局

先为达生物赴港ipo，五大核心问题待补充说明

新股消息 | 先为达生物拟港股上市中国证监会要求补充说明已实施的股权激励方案合规性等

智通财经网

先为达生物IPO：累亏超14亿核心产品市场竞争激烈创始人多次减持股份投后估值近50亿元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/91078"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"91078","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91078\",,,,,undefined,":{"symbol":"91078","market":"HK","secType":"STK","nameCN":"杭州先为达生物科技股份有限公司（临时代码）","latestPrice":0,"timestamp":1770364800000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":0,"latestTime":"02-06 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":7,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1770341400000,1770350400000],[1770354000000,1770364800000]],"volumeRatio":0,"lotSize":100,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91078\",,,,,undefined,":{"symbol":"91078","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91078\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91078\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91078\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91078\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607091264","title":"全球首个cAMP偏向型GLP-1上市！先为达生物改写赛道格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2607091264","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607091264?lang=zh_cn&edition=fundamental","pubTime":"2026-01-30 15:27","pubTimestamp":1769758036,"startTime":"0","endTime":"0","summary":"先颐达®（埃诺格鲁肽注射液）成功获NMPA批准上市，用于成人2型糖尿病患者的血糖控制，成为全球首个获批上市的cAMP偏向型GLP-1受体激动剂。","market":"fut","thumbnail":"https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3726053","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4144","91078","BK4590","GLP"],"gpt_icon":0},{"id":"2591696182","title":"先为达生物赴港ipo，五大核心问题待补充说明","url":"https://stock-news.laohu8.com/highlight/detail?id=2591696182","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591696182?lang=zh_cn&edition=fundamental","pubTime":"2025-12-15 10:10","pubTimestamp":1765764601,"startTime":"0","endTime":"0","summary":"览富财经网讯：12月12日，中国证监会公布最新一期《境外发行上市备案补充材料要求》，本周国际司共仅对8家企业出具补充材料要求，其中今年9月19日，向港交所主板递交上市申请书的杭州先为达生物科技股份有限公司-B ，证监会要求其需补充说明五项事项且需律师核查并出具明确的法律意见。据了解，先为达生物是一家接近商业化阶段的生物医药公司，致力于满足体重管理领域 的迫切医疗需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251215/31865199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["91078"],"gpt_icon":0},{"id":"2590050376","title":"新股消息 | 先为达生物拟港股上市 中国证监会要求补充说明已实施的股权激励方案合规性等","url":"https://stock-news.laohu8.com/highlight/detail?id=2590050376","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590050376?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 19:32","pubTimestamp":1765539141,"startTime":"0","endTime":"0","summary":"中国证监会国际司共对8家企业出具补充材料要求，其中，要求先为达生物补充说明已实施的股权激励方案合规性等事项。据港交所9月19日披露，先为达生物向港交所主板提交上市申请书，摩根士丹利及中金公司为联席保荐人。公司即将在中国推出埃诺格鲁肽注射液，该产品有望成为全球首款cAMP偏向型GLP-1受体激动剂，用于治疗超重/肥胖症及2型糖尿病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["91078"],"gpt_icon":0},{"id":"2576008513","title":"先为达生物IPO：累亏超14亿核心产品市场竞争激烈 创始人多次减持股份投后估值近50亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576008513","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576008513?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 14:39","pubTimestamp":1760683140,"startTime":"0","endTime":"0","summary":"　　近日，杭州先为达生物科技股份有限公司正式向港交所递交主板上市申请。招股书显示，先为达生物成立于2017年，是一家接近商业化阶段的生物医药公司，专注于针对肥胖症及相关疾病的创新体重管理疗法的研发。　　这家成立八年的生物医药企业，在腾讯、IDG资本、美团、正心谷资本等知名机构的多轮投资加持下，最新估值已高达49亿元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-10-17/doc-infuetkq8720872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91078"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/91078\",params:#limit:6,delay:false,,,undefined,":[]}}